Prostate cancer is the second most common cancer among men. As a result, studies have been conducted to find measures to decrease risk of prostate cancer, and moreover its treatment. One of these methods of treatment has been hormonal therapy also known as androgen suppression therapy. This entails use of estrogen to inhibit androgen production by the testicles. The aim of the study is to investigate if different doses of estrogen have an impact on the control of cancer growth. 506 patients with stage 3 and stage 4 prostate cancer were treated with varying doses of estrogen (0.2 mg, 1.0mg and 5.0 mg) while some patients were given a placebo. Fourteen patients had missing values and were therefore excluded from the analysis. At the end of the study, 29.48% of the patients were alive, 25.9% had died of prostate cancer while 44.62% had died of other causes (cerebrovascular, heart or vascular, pulmonary embolus, other cancers etc.) There was no statistically significant effect of history of cardiovascular disease, blood pressure and level of physical activity of the patient on growth of the cancer. There’s no significant impact of estrogen dose level on control of cancer growth.